🔍
☰
Pfizer is currently accepting applications for its RSV and Functional Decline in Hospitalized Adults 2026. Interested applicants are encouraged to click here to learn more about this opportunity and apply for it.
The Pfizer Research Grant Program on Respiratory Syncytial Virus (RSV) in Hospitalized Adults in Italy provides funding for independent research projects that improve understanding of the impact of RSV infection beyond the acute respiratory illness.
The program supports studies that generate real-world evidence on the functional outcomes, healthcare utilization, and long-term consequences of RSV infection among hospitalized adults in Italy. The findings are expected to inform patient risk assessment, preventive strategies, and post-discharge care for vulnerable populations.
Only organizations may apply.
Eligible organizations include:
The institution and the Principal Investigator must both be based in Italy.
Apply for Pfizer - RSV and Functional Decline in Hospitalized Adults
